High glucose accelerates cell proliferation and increases the secretion and mRNA expression of osteopontin in human pancreatic duct epithelial cells

International Journal of Molecular Sciences

Volumn 18, Issue 4, 2017, Pages

  Ito, Miho ^a   Makino, Naohiko ^a   Matsuda, Akiko ^a   Ikeda, Yushi ^a   Kakizaki, Yasuharu ^a   Saito, Yoshihiko ^a   Ueno, Yoshiyuki ^a   Kawata, Sumio ^b  

^a YAMAGATA UNIVERSITY   (Japan)

^b Hyogo Prefectural Nishinomiya Hospital   (Japan)

Author keywords

Diabetes; Human pancreatic duct epithelial cell line (HPDE 6); Hyperinsulinemia; Osteopontin; Pancreatic ductal adenocarcinoma

Indexed keywords

OSTEOPONTIN; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE; GLUCOSE BLOOD LEVEL; INSULIN; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA EXTRACTION; HUMAN; HUMAN CELL; MRNA EXPRESSION ASSAY; OBESITY; PANCREAS CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; RNA INTERFERENCE; SECRETION (PROCESS); TUMOR CELL LINE;

BLOOD GLUCOSE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYGUANOSINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN; OSTEOPONTIN; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 85018495441     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18040807     Document Type: Article

References (31)

1. Japan Pancreas Society. Pancreatic Cancer Registry Report 2007. Suizo 2007, 22, e54.
2. Magruder, J.T.; Elahi, D.; Andersen, D.K. Diabetes and pancreatic cancer: Chicken or egg? Pancreas 2011, 40, 339–351. [CrossRef] [PubMed]
3. Chari, S.T.; Leibson, C.L.; Rabe, K.G.; Timmons, L.J.; Ransom, J.; de Andrade, M.; Petersen, G.M. Pancreatic cancer-associated diabetes mellitus: Prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008, 134, 95–101. [CrossRef] [PubMed]
4. Huxley, R.; Ansary-Moghaddam, A.; Berrington de González, A.; Berrington de González, A.; Barzi, F.; Woodward, M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br. J. Cancer 2005, 92, 2076–2083. [CrossRef] [PubMed]
5. Everhart, J.; Wright, D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995, 273, 1605–1609. [CrossRef] [PubMed]
6. Gapstur, S.M.; Gann, P.H.; Lowe, W.; Liu, K.; Colangelo, L.; Dyer, A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000, 283, 2552–2558. [CrossRef] [PubMed]
7. Takemoto, M.; Yokote, K.; Yamazaki, M.; Ridall, A.L.; Butler, W.T.; Matsumoto, T.; Tamura, K.; Saito, Y.; Mori, S. Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 1999, 258, 722–726. [CrossRef] [PubMed]
8. Hsieh, M.S.; Zhong, W.B.; Yu, S.C.; Lin, J.Y.; Chi, W.M.; Lee, H.M. Dipyridamole suppresses high glucose-induced osteopontin secretion and mRNA expression in rat aortic smooth muscle cells. Circ. J. 2010, 74, 1242–1250. [CrossRef] [PubMed]
9. Gómez-Ambrosi, J.; Catalán, V.; Ramírez, B.; Rodríguez, A.; Colina, I.; Silva, C.; Rotellar, F.; Mugueta, C.; Gil, M.J.; Cienfuegos, J.A.; et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J. Clin. Endocrinol. Metab. 2007, 92, 3719–3727. [CrossRef] [PubMed]
10. Kiefer, F.W.; Zeyda, M.; Todoric, J.; Huber, J.; Geyeregger, R.; Weichhart, T.; Aszmann, O.; Ludvik, B.; Silberhumer, G.R.; Prager, G.; et al. Osteopontin expression in human and murine obesity: Extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 2008, 149, 1350–1357. [CrossRef] [PubMed]
11. Nomiyama, T.; Perez-Tilve, D.; Ogawa, D.; Gizard, F.; Zhao, Y.; Heywood, E.B.; Jones, K.L.; Kawamori, R.; Cassis, L.A.; Tschöp, M.H.; et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Investig. 2007, 117, 2877–2888. [CrossRef] [PubMed]
12. Kiefer, F.W.; Neschen, S.; Pfau, B.; Legerer, B.; Neuhofer, A.; Kahle, M.; Hrabé de Angelis, M.; Schlederer, M.; Mair, M.; Kenner, L.; et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 2011, 54, 2132–2142. [CrossRef] [PubMed]
13. Ahmad, R.; Al-Mass, A.; Al-Ghawas, D.; Shareif, N.; Zghoul, N.; Melhem, M.; Hasan, A.; Al-Ghimlas, F.; Dermime, S.; Behbehani, K. Interaction of osteopontin with IL-18 in obese individuals: Implications for insulin resistance. PLoS ONE 2013, 8, e63944. [CrossRef] [PubMed]
14. Pan, H.W.; Ou, Y.H.; Peng, S.Y.; Liu, S.H.; Lai, P.L.; Lee, P.H.; Sheu, J.C.; Chen, C.L.; Hsu, H.C. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003, 98, 119–127. [CrossRef] [PubMed]
15. Schneider, S.; Yochim, J.; Brabender, J.; Uchida, K.; Danenberg, K.D.; Metzger, R.; Schneider, P.M.; Salonga, D.; Hölscher, A.H.; Danenberg, P.V. Osteopontin but not osteopontin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 1588–1596. [CrossRef] [PubMed]
16. Rudland, P.S.; Platt-Higgins, A.; El-Tanani, M.; de Silva Rudland, S.; Barraclough, R.; Winstanley, J.H.; Howitt, R.; West, C.R. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002, 62, 3417–3427. [PubMed]
17. Poruk, K.E.; Firpo, M.A.; Scaife, C.L.; Adler, D.G.; Emerson, L.L.; Boucher, K.M.; Mulvihill, S.J. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 2013, 42, 193–197. [CrossRef] [PubMed]
18. Butler, A.E.; Galasso, R.; Matveyenko, A.; Rizza, R.A.; Dry, S.; Butler, P.C. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010, 53, 21–26. [CrossRef] [PubMed]
19. Parsa, I.; Longnecker, D.S.; Scarpelli, D.G.; Pour, P.; Reddy, J.K.; Lefkowitz, M. Ductal metaplasia of human exocrine pancreas and its association with carcinoma. Cancer Res. 1985, 45, 1285–1290. [PubMed]
20. Wagner, M.; Weber, C.K.; Bressau, F.; Greten, F.R.; Stagge, V.; Ebert, M.; Leach, S.D.; Adler, G.; Schmid, R.M. Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. Gastroenterology 2002, 122, 1898–1912. [CrossRef] [PubMed]
21. Li, D.; Yeung, S.C.; Hassan, M.M.; Konopleva, M.; Abbruzzese, J.L. Antidiabetic Therapies Affect Risk of Pancreatic Cancer. Gastroenterology 2009, 137, 482–488. [CrossRef] [PubMed]
22. Zakikhani, M.; Dowling, R.; Fantus, I.G.; Sonenberg, N.; Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006, 66, 10269–10273. [CrossRef] [PubMed]
23. Yang, Y.X. Do diabetes drugs modify the risk of pancreatic cancer? Gastroenterology 2009, 137, 412–415. [CrossRef] [PubMed]
24. Sun, J.; Xu, Y.; Dai, Z.; Sun, Y. Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Mol. Cell. Endocrinol. 2009, 313, 64–69. [CrossRef] [PubMed]
25. Kothari, A.N.; Arffa, M.L.; Chang, V.; Blackwell, R.H.; Syn, W.K.; Zhang, J.; Mi, Z.; Kuo, P.C. Osteopontin-A Master Regulator of Epithelial-Mesenchymal Transition. J. Clin. Med. 2016, 5, E39. [CrossRef] [PubMed]
26. Chipitsyna, G.; Gong, Q.; Anandanadesan, R.; Alnajar, A.; Batra, S.K.; Wittel, U.A.; Cullen, D.M.; Akhter, M.P.; Denhardt, D.T.; Yeo, C.J. Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells. Int. J. Cancer 2009, 125, 276–285. [CrossRef] [PubMed]
27. Giardino, I.; Edelstein, D.; Brownlee, M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J. Clin. Investig. 1996, 97, 1422–1428. [CrossRef] [PubMed]
28. Nishikawa, T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404, 787–790. [PubMed]
29. Cowey, S.; Hardy, R.W. The metabolic syndrome: A high-risk state for cancer? Am. J. Pathol. 2006, 169, 1505–1522. [CrossRef] [PubMed]
30. Shibutani, S.; Takeshita, M.; Grollman, A.P. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991, 349, 431–434. [CrossRef] [PubMed]
31. Furukawa, T.; Duguid, W.P.; Rosenberg, L.; Viallet, J.; Galloway, D.A.; Tsao, M.S. Long-Term Culture and Immortalization of Epithelial Cells from Normal Adult Human Pancreatic Ducts Transfected by the E6E7 Gene of Human Papilloma Virus 16. Am. J. Pathol. 1996, 148, 1763–1770. [PubMed]